Aditxt’s Adimune to ship substances for product formulation of of ADI-100

Aditxt (ADTX) provided an update on its subsidiary, Adimune and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes T1D and Stiff Person Syndrome. Adimune’s mission is to address the root causes of autoimmune diseases…All preclinical studies of Adimune’s first product candidate, ADI-100, have been completed, and the shipment of the drug substances for final drug product formulation are planned for March. These studies have provided several data points supporting the potential effectiveness of ADI-100 in restoring durable tolerance over the 10-month duration of the T1D studies both in prevention and treatment study designs. Amro Albanna, Co-Founder, Chairman and CEO of Aditxt, added, “This milestone underscores the significant progress Adimune has made in bringing ADI and ADI-100 to the clinic, with the shipment of the drug substance marking a critical step in that journey. Adimune exemplifies Aditxt’s mission of identifying and accelerating disruptive health innovations. By providing the support and infrastructure needed to advance ADI-100 toward clinical trials, we are reinforcing our commitment to addressing autoimmune diseases as one of the most pressing health challenges we face today.”